Abnormal Vaginal Bleeding During the Early Reproductive Years

2016 ◽  
pp. 1-18
Author(s):  
Anita L. Nelson
Keyword(s):  
Vaginal Bleeding ◽  
Abnormal Vaginal Bleeding

scholarly journals Angiographic features and transarterial embolization of retained placenta with abnormal vaginal bleeding

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Ryo Takaji ◽  
Hiro Kiyosue ◽  
Miyuki Maruno ◽  
Norio Hongo ◽  
Ryuichi Shimada ◽  
...  
Keyword(s):  
Vaginal Bleeding ◽  
Transarterial Embolization ◽  
Recurrent Bleeding ◽  
Study Cohort ◽  
Technical Success ◽  
Retained Placenta ◽  
Vascular Channel ◽  
Abnormal Bleeding ◽  
Abnormal Vaginal Bleeding

Abstract Objectives To clarify characteristic angiographic features and clinical efficacy of selective transarterial embolization (TAE) of retained placenta with abnormal vaginal bleeding. Methods The study cohort comprised 22 patients (mean age, 33.5 years; range, 22–24 years) who underwent selective TAE for retained placenta with abnormal bleeding between January 2018 and December 2020 at our institution. Angiographic images were reviewed by two certified radiologists with consensus. Medical records were reviewed to evaluate the efficacy of TAE. Angiographic features of retained placenta, technical success (disappearance of abnormal findings on angiography), complications, clinical outcomes (hemostatic effects and recurrent bleeding) were evaluated. Results Pelvic angiography showed a dilated vascular channel mimicking arteriovenous fistulas or an aneurysm contiguous with dilated uterine arteries in the mid-arterial–capillary phase in 20 patients; it showed contrast brush in the remaining two patients. TAE technical success was achieved in all patients. No major complications were observed in any patients. Fifteen patients were followed up with expectant management after TAE; all but one patient showed no re-bleeding during the follow-up period (mean follow-up interval, 3.4 months; range, 1–17 months). One patient showed minor rebleeding, which resolved spontaneously. Seven patients underwent scheduled hysteroscopic resection within 1 week after TAE, and no excessive bleeding was observed during or after the surgical procedure in all seven patients. Conclusions The characteristic angiographic feature of retained placenta is “dilated vascular channel that mimic low flow AVM.” TAE is a safe and effective treatment to manage retained placenta with abnormal bleeding.

scholarly journals Five Years’ Experience on Hysteroscopy in Abnormal Vaginal Bleeding

2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Mansoureh Vahdat ◽  
Elaheh Sariri ◽  
Maryam Kashanian ◽  
Zahra Najmi ◽  
Mahjabin Marashi ◽  
...  
Keyword(s):  
Vaginal Bleeding ◽  
Abnormal Vaginal Bleeding

Endometrial Metastases from Gastric Adenocarcinoma: A Case Report

1995 ◽  
Vol 81 (5) ◽  
pp. 383-386 ◽  
Author(s):  
Andrea Pasini ◽  
Piergiorgio Mandelli ◽  
Carlo Belloni
Keyword(s):  
Case Report ◽  
Gastric Adenocarcinoma ◽  
Vaginal Bleeding ◽  
Gastric Tumor ◽  
Uterine Corpus ◽  
Biopsy Specimens ◽  
Abnormal Vaginal Bleeding

Embolic metastases to the endometrium are unusual, especially from extragenital cancers. Metastases in the uterine corpus are generally detected at autospy. We describe a patient with abnormal vaginal bleeding in whom endometrial metastases from an inoperable gastric tumor were discovered in hysteroscopic biopsy specimens.

Abnormal Vaginal Bleeding in Women Desiring Contraception Who Are Taking Anticoagulation Therapy

2018 ◽  
Vol 132 (1) ◽  
pp. 216-217
Author(s):  
Amihai Rottenstreich ◽  
Dvora Bauman ◽  
Yosef Kalish
Keyword(s):  
Vaginal Bleeding ◽  
Anticoagulation Therapy ◽  
Abnormal Vaginal Bleeding

Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin

2017 ◽  
Vol 117 (04) ◽  
pp. 809-815 ◽  
Author(s):  
Suzanne Bleker ◽  
Barbara Hutten ◽  
Anne Timmermans ◽  
Harry Büller ◽  
Saskia Middeldorp ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Diagnostic Tests ◽  
Vaginal Bleeding ◽  
Clinical Presentation ◽  
Diagnostic Procedures ◽  
Absolute Number ◽  
Bleeding Events ◽  
Warfarin Group ◽  
Bleeding Episodes ◽  
Abnormal Vaginal Bleeding

SummaryAbnormal vaginal bleeding can complicate direct oral anticoagulant (DOAC) treatment. We aimed to investigate the characteristics of abnormal vaginal bleeding in patients with venous thromboembolism (VTE) receiving apixaban or enoxaparin/warfarin. Data were derived from the AMPLIFY trial. We compared the incidence of abnormal vaginal bleeding between patients in both treatment arms and collected information on clinical presentation, diagnostic procedures, management and outcomes. In the AMPLIFY trial, 1122 women were treated with apixaban and 1106 received enoxaparin/warfarin. A clinically relevant non-major (CRNM) vaginal bleeding occurred in 28 (2.5 %) apixaban and 24 (2.1 %) enoxaparin/warfarin recipients (odds ratio [OR] 1.2, 95 % confidence interval [CI] 0.7–2.0). Of all CRNM bleeds, 28 of 62 (45 %) and 24 of 120 (20 %) were of vaginal origin in the apixaban and enoxaparin/warfarin group, respectively (OR 3.4; 95 % CI 1.8–6.7). Premenopausal vaginal bleeds on apixaban were characterised by more prolonged bleeding (OR 2.3; 95 %CI 0.5–11). In both pre- and postmenopausal vaginal bleeds, diagnostic tests were performed in six (21 %) and in seven (29 %) apixaban and enoxaparin/ warfarin treated patients, respectively. Medical treatment was deemed not necessary in 16 (57 %) apixaban and 16 (67 %) enoxaparin/warfarin recipients. The severity of clinical presentation and course of the bleeds was mild in 75 % of the cases in both groups. In conclusion, although the absolute number of vaginal bleeding events is comparable between apixaban and enoxaparin/warfarin recipients, the relative occurrence of vaginal bleeds is higher in apixaban-treated women. The characteristics and severity of bleeding episodes were comparable in both treatment arms.

Sign in / Sign up

Export Citation Format

Share Document